Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
McKinsey
Dow
Merck

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Relacorilant

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Relacorilant: Patents, clinical trial progress, indications

Relacorilant is an investigational drug.

There have been 8 clinical trials for Relacorilant. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2018.

The most common disease conditions in clinical trials are Syndrome, Cushing Syndrome, and Ovarian Neoplasms. The leading clinical trial sponsors are Corcept Therapeutics, National Cancer Institute (NCI), and University of Chicago.

There are seven US patents protecting this investigational drug and forty international patents.

Recent Clinical Trials for Relacorilant
TitleSponsorPhase
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerCorcept TherapeuticsPhase 2
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate CancerCorcept TherapeuticsPhase 1
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate CancerNational Cancer Institute (NCI)Phase 1

See all Relacorilant clinical trials

Clinical Trial Summary for Relacorilant

Top disease conditions for Relacorilant
Top clinical trial sponsors for Relacorilant

See all Relacorilant clinical trials

US Patents for Relacorilant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Relacorilant   Start Trial Glucocorticoid receptor modulators to treat pancreatic cancer Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Relacorilant

Drugname Country Document Number Estimated Expiration Related US Patent
Relacorilant Australia 2017323636 2036-09-09   Start Trial
Relacorilant Canada 3034114 2036-09-09   Start Trial
Relacorilant World Intellectual Property Organization (WIPO) 2018049255 2036-09-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Boehringer Ingelheim
Moodys
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.